2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 507

Meta-Analysis of the Time Course of the Response to Adalimumab Plus Methotrexate or Methotrexate Monotherapy in Clinical Trials of Patients with Rheumatoid Arthritis
Abstract Number: 996

Metabolic Control of Invariant Natural Killer T Cell Function
Abstract Number: 2134

Metabolic Reprogramming in the Inflamed Joint Inhibits Pro-Inflammatory Mechanisms
Abstract Number: 1685

Metabolic Syndrome in Patients with Psoriatic Arthritis Is Associated to Peripheral Disease Activity
Abstract Number: 1584

Metabolic Syndrome Is Associated with Disease Activity in Patients with Rheumatoid Arthritis: A Prospective Cohort Study
Abstract Number: 2550

Metabolomic Profiling of Joints in Murine Models of Inflammatory Arthritis
Abstract Number: 574

Metabolomic Profiling Predicts Outcome of Rituximab Therapy in Rheumatoid Arthritis
Abstract Number: 2865

Methotrexate and Leflunomide Survival in Patients with Psoriatic Arthritis
Abstract Number: 579

Methotrexate Does Not Influence 1-Year Bone Mineral Density in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Abstract Number: 2618

Methotrexate Dose May Associated with the Frequency of Lymphoproliferative Disorders in Rheumatoid Arthritis
Abstract Number: 2439

Methotrexate Failure in Pediatric Uveitis
Abstract Number: 1041

Methotrexate Monotherapy and Methotrexate Combination Therapy with Traditional and Biologic Dmards for Rheumatoid Arthritis: A Cochrane Systematic Review and Network Meta-Analysis
Abstract Number: 2724

Methotrexate Treatment Could Modulate the Abnormal CD4+T Lymphocyte Subset Distribution in NaÏve Rheumatoid Arthritis Patients
Abstract Number: 473

Methotrexate, Blood Pressure and Arterial Wave Reflection in Rheumatoid Arthritis
Abstract Number: 1247

Methylation Analysis of HLA-B Locus in Familial Behçet Syndrome

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].